Supplementary Figure 4 from Depleting the Action of EZH2 through PI3K–mTOR Inhibition to Overcome Metastasis and Immunotherapy Resistance in Triple-Negative Breast Cancer

This is a Animal Study study (also classified as: Experimental Study).

Key Points

Nuclear p85β expression was observed in Stage III triple-negative breast cancer patients, influencing treatment strategies.
In 4T1 TNBC mice, paxalisib treatment affected the metastatic process, suggesting a potential therapeutic avenue for patients.
The findings emphasize the role of ezh2 and pi3k-mTOR signaling in mediating immunotherapy resistance.
Understanding these mechanisms may enhance treatment protocols and outcomes in triple-negative breast cancer.

Findings reveal nuclear p85β expression in Stage III TNBC, highlighting the role of pi3k-mTOR in treatment resistance.

Supplementary Figure 4. Nuclear p85β expression in Stage III TNBC patients and paxalisib- treated 4T1 TNBC mice.

No takes yet. Share an insight, caveat, or question.

Melino et al. (2025) studied this question.

View at Publisher

Ask AI

Bookmark

Share